{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:16:39Z","timestamp":1781838999299,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondation pour la Lutte contre le Cancer et pour les Recherches M\u00e9dico-Biologiques","award":["2017"],"award-info":[{"award-number":["2017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13014-018-1112-0","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T08:45:43Z","timestamp":1536050743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I\/II trial"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zwahlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Giaj-Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Koutsouvelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Bertaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Roberto","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Miralbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha\/beta = 1.4 (0.9-2.2) gy. Int J Radiat Oncol Biol Phys. 2012;82:e17\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1112_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","volume":"16","author":"S Aluwini","year":"2015","unstructured":"Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (hypro): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015;16:274\u201383.","journal-title":"Lancet Oncol"},{"key":"1112_CR3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","volume":"35","author":"G Arcangeli","year":"2017","unstructured":"Arcangeli G, Saracino B, Arcangeli S, Gomellini S, Petrongari MG, Sanguineti G, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase iii randomized trial. J Clin Oncol. 2017;35:1891\u20137.","journal-title":"J Clin Oncol"},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 chhip trial. Lancet Oncol. 2016;17:1047\u201360.","journal-title":"Lancet Oncol"},{"key":"1112_CR5","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase iii noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325\u201332.","journal-title":"J Clin Oncol"},{"key":"1112_CR6","first-page":"321","volume":"4","author":"DB Fuller","year":"2014","unstructured":"Fuller DB, Naitoh J, Mardirossian G. Virtual hdr cyberknife sbrt for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations. Front Oncol. 2014;4:321.","journal-title":"Front Oncol"},{"key":"1112_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-9-1","volume":"9","author":"A Katz","year":"2014","unstructured":"Katz A, Kang J. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol. 2014;9:1.","journal-title":"Radiat Oncol"},{"key":"1112_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","volume":"82","author":"CR King","year":"2012","unstructured":"King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:877\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1112_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","volume":"59","author":"R Hannan","year":"2016","unstructured":"Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-results from a multi-institutional clinical trial. Eur J Cancer. 2016;59:142\u201351.","journal-title":"Eur J Cancer"},{"key":"1112_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","volume":"109","author":"CR King","year":"2013","unstructured":"King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase ii trials. Radiother Oncol. 2013;109:217\u201321.","journal-title":"Radiother Oncol"},{"key":"1112_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/153303461000900505","volume":"9","author":"G Bolzicco","year":"2010","unstructured":"Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat. 2010;9:473\u20137.","journal-title":"Technol Cancer Res Treat"},{"key":"1112_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-10-1","volume":"10","author":"AJ Katz","year":"2010","unstructured":"Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1.","journal-title":"BMC Urol"},{"key":"1112_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","volume":"119","author":"PJ Prada","year":"2016","unstructured":"Prada PJ, Cardenal J, Blanco AG, Anchuelo J, Ferri M, Fernandez G, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results. Radiother Oncol. 2016;119:411\u20136.","journal-title":"Radiother Oncol"},{"key":"1112_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","volume":"124","author":"P Hoskin","year":"2017","unstructured":"Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol. 2017;124:56\u201360.","journal-title":"Radiother Oncol"},{"key":"1112_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","volume":"122","author":"G Morton","year":"2017","unstructured":"Morton G, Chung HT, McGuffin M, Helou J, D'Alimonte L, Ravi A, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase ii clinical trial of one fraction of 19gy or two fractions of 13.5gy. Radiother Oncol. 2017;122:87\u201392.","journal-title":"Radiother Oncol"},{"key":"1112_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","volume":"97","author":"DJ Krauss","year":"2017","unstructured":"Krauss DJ, Ye H, Martinez AA, Mitchell B, Sebastian E, Limbacher A, et al. Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-gy single-fraction high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2017;97:98\u2013106.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1112_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the rtog-astro phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1112_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","volume":"76","author":"KM Szymanski","year":"2010","unstructured":"Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245\u201350.","journal-title":"Urology"},{"key":"1112_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The american urological association symptom index for benign prostatic hyperplasia. The measurement committee of the american urological association. J Urol. 1992;148:1549\u201357. discussion 64","journal-title":"J Urol"},{"key":"1112_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.ijir.3900859","volume":"14","author":"EL Rhoden","year":"2002","unstructured":"Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA. The use of the simplified international index of erectile function (iief-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002;14:245\u201350.","journal-title":"Int J Impot Res"},{"key":"1112_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0360-3016(94)90011-6","volume":"30","author":"A Diaz","year":"1994","unstructured":"Diaz A, Roach M 3rd, Marquez C, Coleman L, Pickett B, Wolfe JS, et al. Indications for and the significance of seminal vesicle irradiation during 3d conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;30:323\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1112_CR22","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","volume":"83","author":"HA Gay","year":"2012","unstructured":"Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012;83:e353\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1112_CR23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0360-3016(02)02805-5","volume":"53","author":"KE Wallner","year":"2002","unstructured":"Wallner KE, Merrick GS, Benson ML, Butler WM, Maki J, Tollenaar BG. Penile bulb imaging. Int J Radiat Oncol Biol Phys. 2002;53:928\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1112_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13014-018-1059-1","volume":"13","author":"A Dubouloz","year":"2018","unstructured":"Dubouloz A, Rouzaud M, Tsvang L, Verbakel W, Bjorkqvist M, Linthout N, et al. Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? Radiat Oncol. 2018;13:114.","journal-title":"Radiat Oncol"},{"key":"1112_CR25","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. Eau-estro-siog guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618\u201329.","journal-title":"Eur Urol"},{"key":"1112_CR26","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415\u201324.","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"1112_CR27","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.1016\/S0167-8140(18)30909-5","volume":"127","author":"A Widmark","year":"2018","unstructured":"Widmark A, Gunnlaugson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M. Oc-0599 ultrahypofrcationation for porstate cancer: outcome from the scandinavian phase 3 hypo-rt-pc trial. Radiother Oncol. 2018;127(Suppl. 1):S314.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1112_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.radonc.2017.10.039","volume":"126","author":"A Gomez-Iturriaga","year":"2018","unstructured":"Gomez-Iturriaga A, Casquero F, Pijoan JI, Minguez P, Espinosa JM, Irasarri A, et al. Health-related-quality-of-life and toxicity after single fraction 19gy high-dose-rate prostate brachytherapy: phase ii trial. Radiother Oncol. 2018;126(2):278\u201382.","journal-title":"Radiother Oncol"},{"key":"1112_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","volume":"110","author":"P Hoskin","year":"2014","unstructured":"Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G, et al. High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity. Radiother Oncol. 2014;110:268\u201371.","journal-title":"Radiother Oncol"},{"key":"1112_CR30","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/j.clon.2016.06.013","volume":"28","author":"G D'Agostino","year":"2016","unstructured":"D'Agostino G, Franzese C, De Rose F, Franceschini D, Comito T, Villa E, et al. High-quality linac-based stereotactic body radiation therapy with flattening filter free beams and volumetric modulated arc therapy for low-intermediate risk prostate cancer. A mono-institutional experience with 90 patients. Clin Oncol (R Coll Radiol). 2016;28:e173\u2013e8.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1112_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13014-016-0681-z","volume":"11","author":"Z Chen","year":"2016","unstructured":"Chen Z, Yang Z, Wang J, Hu W. Dosimetric impact of different bladder and rectum filling during prostate cancer radiotherapy. Radiat Oncol. 2016;11:103.","journal-title":"Radiat Oncol"},{"key":"1112_CR32","first-page":"3371","volume":"12","author":"G Reggiori","year":"2010","unstructured":"Reggiori G, Mancosu P, Tozzi A, Cantone MC, Castiglioni S, Lattuada P, et al. Cone beam ct pre- and post-daily treatment for assessing geometrical and dosimetric intrafraction variability during radiotherapy of prostate cancer. J Appl Clin Med Phys. 2010;12:3371.","journal-title":"J Appl Clin Med Phys"}],"updated-by":[{"DOI":"10.1186\/s13014-018-1131-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000}}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-1112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-018-1112-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-1112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:07:53Z","timestamp":1567537673000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-018-1112-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1186\/s13014-018-1112-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13014-018-1131-x","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], the authors reported that one of the authors\u2019 names is spelled incorrectly. In this Correction the incorrect and correct author name are shown. The original publication of this article has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Signature of the informed consent will be obtained from all patients before inclusion in the study.This study was approved by the Ethics committee of the Geneva University Hospital (2017\u201301236) for all Swiss Centers. For Italian centers, the study was approved by the Ethics committee of Istituto Clinico Humanitas (n. 1958). The study is registered on Clinicaltrials.gov (Identifier: NCT03294889; Registered 27 September 2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"166"}}